MiMedx shares falls by 20%
May 10, 2018
Source: drugdu
452
The US-Based MiMedx group's (a manufacturer of regenerative medicine) shares fell 20% after the federal prosecutors charged three healthcare professional for accepting bribes from Mimedx. Of these shares, 7.5% recovered when closing for the day.
It’s been reported that federal prosecutors accused MiMedx of bribing healthcare workers of the Veterans Affairs Department to promote the use of the company's products. The alleged bribes included direct payments, meals, trips and speaking fees.
Neither MiMedx nor any of the company's workers have been directly charged. However, given all of the drama currently going on with the company, it is understandable why traders are shooting first and asking questions later.
This news only makes a bad situation worse say experts, advising people to steer clear of this troubled company and focus their attention on more promising opportunities.
MiMedx Group develops, manufacture and market patent-protected regenerative biomaterial products and bioimplants processed from human amniotic membrane.
By Ddu
Copyright©2024 Ddu. All rights reserved.
Read more on
- Facebook Collaborates with NYU to Develop Faster MRI Scans Using AI August 23, 2018
- $700K Granted to Bot M.D. for International, Doctor-Interactive AI Chatbot App August 10, 2018
- Carisma Therapeutics Bags $53 Million in Series A Funding led by AbbVie June 28, 2018
- FDA Anounces Restricted use of Keytruda & Tecentriq Against Bladder Cancer June 26, 2018
- Vertex Pharma Doubles Cystic Fibrosis Research Facility June 20, 2018
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
